Taysha Gene Therapies, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
Taysha Gene Therapies, Inc. (TSHA) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of 5.89% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2025-02-26
- Taysha Gene Therapies, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2024 was 5.89%.
- Taysha Gene Therapies, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2023 was -18.98%, a 486.56% decline from fiscal 2022.
- Taysha Gene Therapies, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2022 was 4.91%, a 36.07% decline from fiscal 2021.
- Taysha Gene Therapies, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2021 was 7.68%, a 624.53% increase from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month |
|---|---|
| 2024-12-31 | 5.89% 10-K · filed 2025-02-26 |
| 2023-12-31 | -18.98% 10-K · filed 2025-02-26 |
| 2022-12-31 | 4.91% 10-K · filed 2024-03-19 |
| 2021-12-31 | 7.68% 10-K · filed 2023-03-28 |
| 2020-12-31 | 1.06% 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |